Abstract Library

#3397 Molecular deciphering of primary liver neuroendocrine neoplasms confirms its distinct existence with foregut-like profile

Introduction: Isolated hepatic localizations of neuroendocrine tumors (NETs) are generally considered as metastatic NETs of unknown primary but could correspond to primary hepatic NETs (PHNETs), a poorly explored entity.

Conference:

Presenting Author:

Authors: de Mestier L, Nicolle R, Poté N, Rebours V, Hentic O,

Keywords: liver, unknown primary, DNA sequencing, RNA sequencing, immunohistochemistry,

#3361 FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors

Introduction: Well-differentiated neuroendocrine tumors (NETs) are relatively rare, highly vascularized neoplasms. Antiangiogenic drugs have shown efficacy in patients with advanced NETs. Bevacizumab is a well-known antiangiogenic monoclonal antibody.

Conference:

Presenting Author:

Authors: Lacombe C, Perrier M, Hentic O, Brixi H, Rebours V,

Keywords: neuroendocrine tumor, antiangiogenic therapy, VEGF, well-differentiated,

#1900 Well-Differentiated G1/G2 Pancreatic NETs Can Evolve Towards G3 Tumors

Introduction: Well-differentiated G1/G2 pancreatic NET (pNET) may evolve towards well-differentiated G3 pNET or carcinoma (pNEC)

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Olivia H

Authors: Hentic O, Cros J, Rebours V, Zappa M, Muller N,

Keywords: dedifferentiation, new biopsy,

#1557 Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET

Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: CROS J

Authors: Bucau M, Cros J, Raffenne J, Rebours V, Palazzo M,

Keywords: PNET, everolimus, predictive biomarkers,

#1546 O6-Methylguanine DNA Methyltransferase (MGMT) Expression by Immunochemistry May Help Predict Response to Streptozotocin-based Chemotherapy in Pancreatic Neuroendocrine Tumours

Introduction: Streptozotocin (STZ) is an alkylating agent inducing DNA damage mainly repaired by MGMT. STZ-based chemotherapy is the first line treatment of non-resectable well-differentiated PNET. As for temozolomide, tumour MGMT deficiency may predict the efficacy of STZ in PNET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Hentic O

Authors: Hentic O, Cros J, Zappa M, Rebours V, Muller N,

Keywords: MGMT, Streptozotocin, PFS ,